Idursulfase (Elaprase®)

Elaprase (idursulfase) is covered only for the FDA‑approved indication, mucopolysaccharidosis type II (Hunter syndrome); use for other indications is not supported. Coverage requires documented deficient iduronate‑2‑sulfatase activity or an IDS gene mutation, prescription by or consultation with a geneticist/endocrinologist/metabolic or lysosomal storage disorder specialist, approvals up to 12 months, dosing limited to 0.5 mg/kg IV no more than once weekly, and meeting applicable safety criteria.

"Treatment of individuals with mucopolysaccharidosis type II (MPS II; Hunter syndrome) — FDA-approved indication."

Sign up to see full coverage criteria, indications, and limitations.